赖氨酰氧化酶
小梁切除术
医学
血管生成
青光眼
纤维化
青光眼手术
病理
伤口愈合
免疫组织化学
泡（药）
眼科
免疫学
癌症研究
细胞外基质
化学
生物化学
作者
Tine Van Bergen,Derek Marshall,Sara Van de Veire,Evelien Vandewalle,Lieve Moons,Jean Herman,Victoria Smith,Ingeborg Stalmans
标识
DOI：10.1167/iovs.13-11696
摘要
Targeting LOXL2 with an inhibitory monoclonal antibody (GS-607601) reduced pathologic angiogenesis, inflammation, and fibrosis. These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
大力的冬萱
Copyright
cdercder
OK
舒适的如萱
MozzieMiao
天晴
Nole
liuzhuohao
潇洒的惋清
arniu2008
我们去哪li
科研狗
Nexus
lizishu
sagitar
sanvva
殷勤的紫槐
愉快的真
皖公网安备34019202002308
